Incyte prices 10.5M share offering
US drug discovery firm Incyte Corp has announced the pricing of its underwritten public offering of 10,500,000 shares of its common stock at a price to the public of $9.00 each. The size of the offering was increased from the originally announced 9,000,000 shares. Incyte also granted the underwriters a 30-day option to purchase an additional 1,575,000 shares of common stock. All of the shares are being offered by Incyte.
The company intends to use the net proceeds of this offering for general corporate purposes, including research and development activities.
Goldman Sachs is acting as sole book-running manager and Morgan Stanley as joint lead manager, with JP Morgan Securities as co-manager.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze